Literature DB >> 6698657

Acarbose in reactive hypoglycemia: a double-blind study.

J Gérard, A S Luyckx, P J Lefèbvre.   

Abstract

This study investigates the effect of Acarbose, a complex oligosaccharide of microbial origin with glucosidase-inhibiting properties in alimentary hypoglycemia secondary to rapid gastric emptying and in reactive hypoglycemia either isolated or associated with impaired glucose tolerance. Twenty-four patients complaining of symptoms suggesting hypoglycemia which occurred after meals and who showed blood glucose values of 2.5 mmol/l (45 mg/dl) or below on one or more occasions during a 5-h oral glucose tolerance test were selected and divided into three groups. Group I comprized seven patients with demonstrated rapid gastric emptying; group II comprized eight patients with impaired glucose tolerance, whereas the nine patients of group III were considered to present with "isolated reactive hypoglycemia" since they had a normal glucose tolerance and did not have either glycosuria or gastroduodenal pathology. All patients were submitted to two oral 75-g sucrose tolerance tests. Acarbose (100 mg) or placebo was ingested with the first drought of the sucrose solution administered in a randomized order. The investigation was performed in a double-blind manner. In all three groups Acarbose significantly reduced the magnitude of post-sucrose reactive hypoglycemia. The blood glucose nadir also occurred later, but this effect was statistically significant in group II only. In patients of groups II and III, such improvement of the glucose nadirs was preceded by a significant reduction of the post-sucrose glycemic peak. In all three groups, the insulin response to oral sucrose was reduced by Acarbose. Another consistent finding was the lack of sucrose-induced glucagon suppression when Acarbose was given. These data suggest that Acarbose might be a useful adjunct to the management of functional hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6698657

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  7 in total

Review 1.  Pharmacokinetic-pharmacodynamic relationships of Acarbose.

Authors:  T Salvatore; D Giugliano
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 2.  Pathophysiology, diagnosis and management of postoperative dumping syndrome.

Authors:  Jan Tack; Joris Arts; Philip Caenepeel; Dominiek De Wulf; Raf Bisschops
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-01       Impact factor: 46.802

3.  Long-term treatment with acarbose for the treatment of reactive hypoglycemia.

Authors:  A G Ozgen; F Hamulu; F Bayraktar; S Cetínkalp; C Yilmaz; M Túzún; T Kabalak
Journal:  Eat Weight Disord       Date:  1998-09       Impact factor: 4.652

4.  Combined Dipeptidyl Peptidase 4 Inhibitor and α-Glucosidase Inhibitor Treatment in Postprandial Hypoglycemia.

Authors:  David T Broome; Alimitha Kodali; Danielle Phillips; Vinni Makin; Daniel Mendlovic; Robert S Zimmerman
Journal:  Clin Diabetes       Date:  2022-01

Review 5.  Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  S P Clissold; C Edwards
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

Review 6.  A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.

Authors:  F Santeusanio; P Compagnucci
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

Review 7.  International consensus on the diagnosis and management of dumping syndrome.

Authors:  Emidio Scarpellini; Joris Arts; George Karamanolis; Anna Laurenius; Walter Siquini; Hidekazu Suzuki; Andrew Ukleja; Andre Van Beek; Tim Vanuytsel; Serhat Bor; Eugene Ceppa; Carlo Di Lorenzo; Marloes Emous; Heinz Hammer; Per Hellström; Martine Laville; Lars Lundell; Ad Masclee; Patrick Ritz; Jan Tack
Journal:  Nat Rev Endocrinol       Date:  2020-05-26       Impact factor: 43.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.